Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis

Mengdie Hu 1, Xiaoling Cai 1, Wenjia Yang 1, Simin Zhang 1, Lin Nie 2, Linong Ji 1

Main idea: Treatment with GLP-1RA and SGLT2i led to significant reductions in BP in patients with type 2 diabetes mellitus. Weight reduction was significantly and independently associated with BP reductions in GLP-1RA treatment and SGLT2i treatment.

Abstract

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have shown beneficial effects on cardiovascular outcomes and multiple cardiovascular risk factors, including hypertension. The mechanism of blood pressure (BP)-lowering effects of these agents has not been elucidated. This study aims to evaluate the effect of hemoglobin A1c reduction or body weight reduction on BP changes in patients with type 2 diabetes mellitus. A total of 184 trials were included and the authors found no link between weight loss and systolic BP reduction or diastolic BP reductions for either drug class. The authors conclude that the drugs had little effect on blood pressure changes in these patients. 

Source NIH